Precision Oncology News: Lantern Pharma Preparing IND for Synthetic Lethality Program With FDA Feedback
Jan 17, 2023 | staff reporter
NEW YORK – Lantern Pharma on Tuesday said it received feedback from the US Food and Drug Administration that it will use to submit an investigational new drug application for LP-184. The company further plans to begin studying the drug in a Phase I trial of patients with solid tumors, including cancers with DNA damage repair deficiency, in the second quarter of 2023.
The Dallas-based company requested a pre-IND meeting with the agency at the end of 2022 to gather feedback on its plans for LP-184. Based on the agency’s input, Lantern is optimistic it will be able to start a Phase I trial for LP-184 next quarter and begin enrolling patients with pancreatic cancer, malignant gliomas, and select solid tumors with DNA damage repair deficiency.